• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease.沉默调节蛋白-1、低密度脂蛋白胆固醇与高密度脂蛋白功能的相互作用:一项比较能量限制和阿托伐他汀对早发性冠状动脉疾病女性影响的随机对照试验。
Antioxidants (Basel). 2022 Nov 29;11(12):2363. doi: 10.3390/antiox11122363.
2
Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.10毫克与80毫克阿托伐他汀对稳定型冠状动脉疾病患者高敏C反应蛋白的比较效应:CAP(阿托伐他汀多效性比较)研究结果
Clin Ther. 2008 Dec;30(12):2298-313. doi: 10.1016/j.clinthera.2008.12.023.
3
N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.N-3 脂肪酸补充剂与他汀类药物联合使用可调节血脂谱,包括小而密 LDL:一项随机、双盲、安慰剂对照试验。
Lipids Health Dis. 2022 Sep 1;21(1):84. doi: 10.1186/s12944-022-01686-y.
4
Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.比较匹伐他汀与阿托伐他汀在血脂异常和冠心病患者中升高高密度脂蛋白胆固醇和脂联素的作用:COMPACT-CAD 研究。
J Cardiol. 2013 Aug;62(2):87-94. doi: 10.1016/j.jjcc.2013.03.008. Epub 2013 May 11.
5
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.强化降脂治疗与中度降脂治疗对冠状动脉粥样硬化进展的影响:一项随机对照试验。
JAMA. 2004 Mar 3;291(9):1071-80. doi: 10.1001/jama.291.9.1071.
6
Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open-label, randomized, blinded-end point (probe) trial.80毫克缓释氟伐他汀与20毫克阿托伐他汀对2型糖尿病且血清高密度脂蛋白胆固醇水平较低患者的代谢影响:一项为期4个月的前瞻性、开放标签、随机、双盲终点(探索性)试验。
Curr Ther Res Clin Exp. 2004 Jul;65(4):330-44. doi: 10.1016/j.curtheres.2004.06.004.
7
Pitavastatin: novel effects on lipid parameters.匹伐他汀:对血脂参数的新作用。
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.
8
LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study.心血管疾病且高密度脂蛋白胆固醇(HDL-C)水平低的受试者的低密度脂蛋白胆固醇(LDL-C)/HDL-C 比值:RADAR(瑞舒伐他汀和阿托伐他汀不同剂量与胆固醇逆向转运)研究结果
Curr Med Res Opin. 2005 Nov;21(11):1865-74. doi: 10.1185/030079905X74952.
9
10
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.瑞舒伐他汀与阿托伐他汀、辛伐他汀及普伐他汀对高胆固醇血症患者非高密度脂蛋白胆固醇、载脂蛋白及脂质比值的影响:STELLAR试验的额外结果
Clin Ther. 2004 Sep;26(9):1388-99. doi: 10.1016/j.clinthera.2004.09.006.

引用本文的文献

1
Editorial Commentary on the Special Issue "Antioxidant Therapy for Cardiovascular Diseases"-Cutting-Edge Insights into Oxidative Stress and Antioxidant Therapy in Cardiovascular Health.关于“心血管疾病的抗氧化治疗——心血管健康中氧化应激与抗氧化治疗的前沿见解”特刊的社论评论
Antioxidants (Basel). 2024 Aug 26;13(9):1034. doi: 10.3390/antiox13091034.
2
The Multifaceted Role of Endothelial Sirt1 in Vascular Aging: An Update.内皮 Sirt1 在血管衰老中的多效作用:最新研究进展。
Cells. 2024 Sep 1;13(17):1469. doi: 10.3390/cells13171469.
3
Sirtfood intake in relation to the 10-year risk of major adverse cardiovascular events: a population-based cohort study.与主要不良心血管事件10年风险相关的Sirtfood摄入量:一项基于人群的队列研究。
Nutr Metab (Lond). 2024 May 10;21(1):24. doi: 10.1186/s12986-024-00798-9.
4
Red Blood Cells' Omega-6 and Omega-3 Polyunsaturated Fatty Acids Have a Distinct Influence on LDL Particle Size and its Structural Modifications.红细胞的ω-6 和 ω-3 多不饱和脂肪酸对 LDL 颗粒大小及其结构修饰有明显影响。
Arq Bras Cardiol. 2023 Nov;120(11):e20230078. doi: 10.36660/abc.20230078.
5
Stearic Acid, but not Palmitic Acid, is Associated with Inflammatory and Endothelial Dysfunction Biomarkers in Individuals at Cardiovascular Risk.硬脂酸与心血管风险个体的炎症和内皮功能障碍生物标志物相关,而棕榈酸则没有。
Arq Bras Cardiol. 2023 Sep 1;120(8):e20220598. doi: 10.36660/abc.20220598. eCollection 2023.
6
Sirtuin 1 and Vascular Function in Healthy Women and Men: A Randomized Clinical Trial Comparing the Effects of Energy Restriction and Resveratrol.Sirtuin 1 和血管功能在健康女性和男性中的作用:一项比较能量限制和白藜芦醇影响的随机临床试验。
Nutrients. 2023 Jun 29;15(13):2949. doi: 10.3390/nu15132949.

本文引用的文献

1
Sex Differences in Cardiovascular Disease Mortality in Brazil between 1996 and 2019.1996 年至 2019 年巴西心血管疾病死亡率的性别差异。
Int J Environ Res Public Health. 2022 Oct 7;19(19):12827. doi: 10.3390/ijerph191912827.
2
Effects of Coffee on Sirtuin-1, Homocysteine, and Cholesterol of Healthy Adults: Does the Coffee Powder Matter?咖啡对健康成年人的沉默信息调节因子1、同型半胱氨酸和胆固醇的影响:咖啡粉重要吗?
J Clin Med. 2022 May 25;11(11):2985. doi: 10.3390/jcm11112985.
3
Omega-3 Fatty Acids in Erythrocyte Membranes as Predictors of Lower Cardiovascular Risk in Adults without Previous Cardiovascular Events.红细胞膜中的ω-3脂肪酸作为无既往心血管事件的成年人心血管风险降低的预测指标
Nutrients. 2021 Jun 3;13(6):1919. doi: 10.3390/nu13061919.
4
Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial.白藜芦醇补充与能量限制对交感神经系统活性和血管反应性影响的比较:一项随机临床试验。
Molecules. 2021 May 26;26(11):3168. doi: 10.3390/molecules26113168.
5
Effect of intermittent and continuous caloric restriction on Sirtuin1 concentration depends on sex and body mass index.间歇性和持续性热量限制对沉默调节蛋白1浓度的影响取决于性别和体重指数。
Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1871-1878. doi: 10.1016/j.numecd.2021.03.005. Epub 2021 Mar 19.
6
Improved risk assessment of coronary artery disease by substituting paraoxonase 1 activity for HDL-C: Novel cardiometabolic biomarkers based on HDL functionality.通过替代载脂蛋白 1 活性来评估冠心病风险:基于高密度脂蛋白功能的新型代谢相关心血管生物标志物。
Nutr Metab Cardiovasc Dis. 2021 Apr 9;31(4):1166-1176. doi: 10.1016/j.numecd.2020.12.026. Epub 2021 Jan 1.
7
Risk Factor Burden and Long-Term Prognosis of Patients With Premature Coronary Artery Disease.早发性冠心病患者的风险因素负担和长期预后。
J Am Heart Assoc. 2020 Dec 15;9(24):e017712. doi: 10.1161/JAHA.120.017712. Epub 2020 Dec 8.
8
Reduced leukocyte telomere lengths and sirtuin 1 gene expression in long-term survivors of type 1 diabetes: A Dialong substudy.1 型糖尿病长期幸存者白细胞端粒长度缩短和 SIRT1 基因表达降低:Dialong 子研究。
J Diabetes Investig. 2021 Jul;12(7):1183-1192. doi: 10.1111/jdi.13470. Epub 2020 Dec 30.
9
Cardiovascular Disease in Women: From Pathophysiology to Novel and Emerging Risk Factors.女性心血管疾病:从病理生理学到新型和新兴风险因素。
Heart Lung Circ. 2021 Jan;30(1):9-17. doi: 10.1016/j.hlc.2020.05.108. Epub 2020 Jul 6.
10
Shorter Leukocyte Telomere Lengths in Healthy Relatives of Patients with Coronary Heart Disease.冠心病患者健康亲属的端粒长度较短。
Rejuvenation Res. 2020 Aug;23(4):324-332. doi: 10.1089/rej.2019.2258. Epub 2020 Jan 14.

沉默调节蛋白-1、低密度脂蛋白胆固醇与高密度脂蛋白功能的相互作用:一项比较能量限制和阿托伐他汀对早发性冠状动脉疾病女性影响的随机对照试验。

The Interplay of Sirtuin-1, LDL-Cholesterol, and HDL Function: A Randomized Controlled Trial Comparing the Effects of Energy Restriction and Atorvastatin on Women with Premature Coronary Artery Disease.

作者信息

Leal Dalila Pinheiro, Gonçalinho Gustavo Henrique Ferreira, Tavoni Thauany Martins, Kuwabara Karen Lika, Paccanaro Ana Paula, Freitas Fatima Rodrigues, Strunz Célia Maria Cassaro, César Luiz Antonio Machado, Maranhão Raul Cavalcante, Mansur Antonio de Padua

机构信息

Faculdade de Medicina da Universidade de São Paulo, University of São Paulo, Sao Paulo 05508-060, Brazil.

Servico de Prevencao, Cardiopatia da Mulher e Reabilitacao Cardiovascular, Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo 05403-900, Brazil.

出版信息

Antioxidants (Basel). 2022 Nov 29;11(12):2363. doi: 10.3390/antiox11122363.

DOI:10.3390/antiox11122363
PMID:36552571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9774144/
Abstract

INTRODUCTION

HDL function has gained prominence in the literature as there is a greater predictive capacity for risk in early coronary artery disease when compared to the traditional parameters. However, it is unclear how dietary energy restriction and atorvastatin influence HDL function.

METHODS

A randomized controlled trial with 39 women with early CAD divided into three groups (n = 13): energy restriction (30% of VET), atorvastatin (80 mg), and control. Analyses of traditional biochemical markers (lipid and glucose profile), circulating Sirt-1, and HDL function (lipid composition, lipid transfer, and antioxidant capacity).

RESULTS

Participants' mean age was 50.5 ± 3.8 years. Energy restriction increased Sirt-1 by 63.6 pg/mL (95%CI: 1.5-125.7; = 0.045) and reduced BMI by 0.8 kg/m (95%CI: -1.349--0.273; = 0.004) in a manner independent of other cardiometabolic factors. Atorvastatin reduced LDL-c by 40.0 mg/dL (95%CI: -69.910--10.1; = 0.010). Increased Sirt-1 and reduced BMI were independently associated with reduced phospholipid composition of HDL (respectively, β = -0.071; CI95%:-0.136--0.006; = 0.033; β = 7.486; CI95%:0.350-14.622; = 0.040). Reduction in BMI was associated with lower HDL-free cholesterol (β = 0.818; CI95%:0.044-1.593; = 0.039). LDL-c reduction by statins was associated with reduced maximal lipid peroxide production rate of HDL (β = 0.002; CI95%:0.000-0.003; = 0.022) and total conjugated diene generation (β = 0.001; CI95%:0.000-0.001; = 0.029).

CONCLUSION

This study showed that energy restriction and atorvastatin administration were associated with changes in lipid profile, serum Sirt-1 concentrations, and HDL function.

摘要

引言

高密度脂蛋白(HDL)的功能在文献中备受关注,因为与传统参数相比,它对早期冠状动脉疾病风险具有更强的预测能力。然而,目前尚不清楚饮食能量限制和阿托伐他汀如何影响HDL功能。

方法

一项随机对照试验,纳入39例早期冠心病女性患者,分为三组(每组n = 13):能量限制组(占基础能量消耗的30%)、阿托伐他汀组(80毫克)和对照组。分析传统生化指标(血脂和血糖谱)、循环中的沉默信息调节因子1(Sirt-1)以及HDL功能(脂质组成、脂质转运和抗氧化能力)。

结果

参与者的平均年龄为50.5±3.8岁。能量限制使Sirt-1升高63.6 pg/mL(95%置信区间:1.5 - 125.7;P = 0.045),并使体重指数(BMI)降低0.8 kg/m²(95%置信区间:-1.349 - -0.273;P = 0.004),且独立于其他心血管代谢因素。阿托伐他汀使低密度脂蛋白胆固醇(LDL-c)降低40.0 mg/dL(95%置信区间:-69.910 - -10.1;P = 0.010)。Sirt-1升高和BMI降低分别独立与HDL磷脂组成减少相关(β = -0.071;95%置信区间:-0.136 - -0.006;P = 0.033;β = 7.486;95%置信区间:0.350 - 14.622;P = 0.040)。BMI降低与HDL游离胆固醇降低相关(β = 0.818;95%置信区间:0.044 - 1.593;P = 0.039)。他汀类药物降低LDL-c与HDL最大脂质过氧化物生成率降低相关(β = 0.002;95%置信区间:0.000 - 0.003;P = 0.022)以及总共轭二烯生成降低相关(β = 0.001;95%置信区间:0.000 - 0.001;P = 0.029)。

结论

本研究表明,能量限制和阿托伐他汀治疗与血脂谱、血清Sirt-1浓度及HDL功能的变化相关。